Research and Markets: Currently it Takes an Estimated 7-10 Years to Develop and Market a Drug at a Cost That Exceeds $800 Million

Nov 02, 2004, 00:00 ET from Research and Markets

    DUBLIN, Ireland, Nov. 2 /PRNewswire/ -- Pharmaceutical and biotechnology
 companies are under immense pressures to produce a steady stream of
 innovative, well-differentiated drugs at reduced costs. In simple terms, drug
 discovery requires the identification of a disease, knowledge of the disease
 mechanism and identification of a target (point of intervention).
     (Logo: )
     Research and Markets ( has
 announced the addition of The Impact of Nanotechnology in Drug Discovery:
 Global Developments, Market Analysis and Future Prospects to their offering.
     The human genome project is expected to identify approximately 100,000
 targets that will require evaluation against many compound libraries to
 compare gene sequences and structure. This represents a very time-consuming
 process and a major bottleneck in the drug discovery process as millions of
 compounds can be screened for each target. Novel discovery and validation
 technologies can expand the hit rate for promising compounds in the pipeline,
 and expedite their progress through to market. The introduction of microarrays
 and lab-on-a-chip technologies has already revolutionized the drug discovery
     Where once it took the effort of a single chemist to view anything from
 one to 12 gene variations at a time, microarrays can view thousands in the
 same time frame. Now, nanotechnology promises to exponentially increase even
 the volume of microarrays by working at a level far smaller than conventional
 microarrays and according to one source the pharmaceutical market will
 represent approximately $180 billion of the forecasted $1 trillion nanotech
     Nanotechnology can enhance the drug discovery process, through
 miniaturization, automation, speed and reliability of assays. Although at an
 embryonic stage of development, nano-enabled drugs are already bringing
 clinical benefits to thousands of patients. This report provides an overview
 and a detailed analysis of the major drivers, restraints and challenges for
 current and emerging applications of nanotechnology in drug discovery.
     Areas covered include nano-enabled drug discovery technologies/tools,
 nano-enabled drugs and an assessment of key market engineering parameters. The
 technologies/tools covered include, nanoarrays, nanomasspectrometry,
 nanolithography arrays, biological chips, congruent force intermolecular test
 and solubility and reformulation methods.
     This report provides global market coverage and discusses funding,
 regulatory and ethical issues in the major industrial countries, with
 worldwide market forecasts over a 5-year forecast period. This report will be
 of vital interest to strategic planners, marketing managers and product
 development managers at all pharmaceutical, diagnostic, life science and
 biotechnology companies that may be interested in nanotechnology.
 This report may also benefit individuals and investors who track advances in
 the evolving nanotechnology market, including venture capitalists, healthcare
 equity analysts, academic research and scientific staff.
     The contents of this report are as follows:
      - Executive Summary
      - Chapter One: Introduction
      - Chapter Two: Challenges, drivers and restraints
      - Chapter Three: Applications of nanotechnology in drug discovery
      - Chapter Four: Industrial Participants
      - Chapter Five: Global market analysis
      - Chapter Six: Strategic analysis and recommendations
      - Chapter Seven
      - Appendix A
      - Terms and definitions
      - Acronyms and abbreviations used in this report
     For more information visit
      Laura Wood
      Senior Manager
      Research and Markets
      Fax: +353 1 4100 980

SOURCE Research and Markets